Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 0.42 |
| ▸ | MAOA | P21397 | 8/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | CALML3 | P27482 | 1/20 | 0.42 |
| ▸ | SDHA | P31040 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 4/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7081135 | 0.94 | MAOB (0.43) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL7078247 | 0.84 | F10 (0.54) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL7078251 | 0.84 | F10 (0.54) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL7078273 | 0.84 | F10 (0.53) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL7079351 | 0.84 | F10 (0.53) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL7078275 | 0.84 | F10 (0.53) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL7079349 | 0.84 | F10 (0.53) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL7807718 | 0.84 | CALML3 (0.51) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL7807715 | 0.84 | CALML3 (0.51) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL7807712 | 0.84 | CALML3 (0.51) | MAOBMAOALMNAPTGS1CALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6617339-B1 | 5-Isoxazolyloxymethyl-3-((dihydroxypropanoyl)-4-tetrahydropyri dyl-3,5- difluorophenyl)oxazolidinone, or the phosphated derivative or its disodium salt; antibiotic with useful activity against Grampositive pathogens | SYNGENTA LIMITED (GB) | 2003-09-09 | — | — | US | disclosed |
| US-20030144263-A1 | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them | SYNGENTA LIMITED (GB) | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144263-A1 | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them | CYP3A5, CYP2D6, OXA1L | MAOB 1178/4885MAOA 1654/4885LMNA 3058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.